结构性痛苦筛查与支持治疗用于接受全身治疗的肺癌患者:一项随机对照试验
本研究将新诊断或复发性肺癌开始全身治疗的患者随机分为常规护理组与实验性支持护理组(由心理社会护士定期评估痛苦并转诊)。共223例患者随机分组,主要结局为EORTC-QLQ-C30整体生活质量评分1至25周平均变化,两组无显著差异,实验组临终前短期内接受化疗的患者较少,中位生存期相当。
要点
- 心理社会护士主导的结构性痛苦筛查与转诊未改善肺癌患者生活质量。
- 实验组临终前短期内接受化疗的患者少于常规护理组。
- 两组中位生存期相当(10.3个月 vs 10.1个月,P=0.62)。
核心结论
- 该支持护理方法未改善肺癌患者的生活质量及其他患者报告结局,但减少了临终前短期内化疗的使用。
- 作者认为全身治疗的(晚期)副作用可能掩盖了干预对生活质量的影响。
研究设计与样本
- 随机对照试验,纳入新诊断或复发性肺癌开始全身治疗的患者,随机分为常规护理组或实验性支持护理组。
- 共223例患者随机分组,其中111例(50%)完成全部四次评估(常规护理组44% vs 实验组55%)。
- 在随机分组后第1、7、13和25周使用EORTC-QLQ-C30、欧洲五维健康量表、医院焦虑抑郁量表和患者满意度问卷-III进行随访。
- 主要结局为EORTC-QLQ-C30整体生活质量评分在第1周至第25周之间的平均变化。
主要发现
- 整体生活质量评分平均变化无显著差异(-2.4,95%CI:12.1-7.2;P=0.61),其他患者报告结局亦无显著差异。
- 实验组临终前短期内接受化疗的患者较少。
- 中位生存期相当(10.3个月 vs 10.1个月,P=0.62)。
- 112例退出者中,33例死亡,79例因其他原因停止参与。
局限性
- 作者认为全身治疗的(晚期)副作用可能掩盖了干预对生活质量的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Gaining regular insight into the nature and severity of distress by a psychosocial nurse coupled with referral to psychosocial and/or paramedical healthcare provider(s) is an experimental supportive care approach. We sought to examine the effects of this approach on quality of life (QoL), patient's mood and satisfaction, end-of-life care and survival in patients with lung cancer. METHODS: Patients with newly diagnosed or recurrent lung cancer starting systemic therapy were randomly assigned to receive usual care or the experimental approach. Patients were followed up at 1, 7, 13 and 25 weeks after randomisation with the EORTC-QLQ-C30, the European Quality of Life-5D, the Hospital Anxiety and Depression Scale and the Patient Satisfaction Questionnaire-III. Primary outcome was the mean change in the EORTC-QLQ-C30 global QoL-score between 1 and 25 weeks. RESULTS: A total of 223 patients were randomised of whom 111 (50%) completed all four assessments (44% in the usual care group versus 55% in the experimental group). No significant difference was found in the mean change global QoL-score (-2.4, 95% CI: 12.1-7.2; P = 0.61), nor in the other patient-reported outcomes. Fewer patients in the experimental group received chemotherapy shortly before the end-of-life, and median survival was comparable (10.3 versus 10.1 months, P = 0.62). Of the 112 dropouts, 33 died and 79 discontinued participation for other reasons. CONCLUSIONS: This supportive care approach neither improved QoL nor other patient-reported outcomes in patients with lung cancer. However, it reduced the use of chemotherapy shortly before the end of life. Possibly, (late) side effects of systemic therapy may have obscured effects of our intervention on QoL. CLINICAL TRIAL REGISTRATION: NTR3540.
引用
- Geerse OP, Hoekstra-Weebers JE, Stokroos MH, et al. Structural distress screening and supportive care for patients with lung cancer on systemic therapy: A randomised controlled trial. Eur J Cancer. 2016. PMID: 28024265. doi:10.1016/j.ejca.2016.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。